Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2799

1.

Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study.

Strzelecki D, Szyburska J, Kotlicka-Antczak M, Kałużyńska O.

Neuropsychiatr Dis Treat. 2015 Feb 27;11:533-6. doi: 10.2147/NDT.S75734. eCollection 2015.

2.

Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation.

Matosin N, Fernandez-Enright F, Fung SJ, Lum JS, Engel M, Andrews JL, Huang XF, Weickert CS, Newell KA.

Acta Neuropathol. 2015 Mar 17. [Epub ahead of print]

PMID:
25778620
3.

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia.

Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, Brenner R, Rayle TJ, Nisenbaum L, Zhao F, Gomez JC.

BMC Psychiatry. 2014 Dec;14(1):351. doi: 10.1186/s12888-014-0351-3. Epub 2014 Dec 10.

4.

Metabotropic Glutamate Receptors in Central Nervous System Diseases.

Golubeva AV, Moloney RD, O'Connor RM, Dinan TG, Cryan JF.

Curr Drug Targets. 2015 Mar 16. [Epub ahead of print]

PMID:
25777273
5.
6.

The kynurenine pathway and neurodegenerative disease.

Maddison DC, Giorgini F.

Semin Cell Dev Biol. 2015 Mar 12. pii: S1084-9521(15)00045-2. doi: 10.1016/j.semcdb.2015.03.002. [Epub ahead of print] Review.

PMID:
25773161
7.

α2-Adrenoceptors in the treatment of major neuropsychiatric disorders.

Langer SZ.

Trends Pharmacol Sci. 2015 Mar 12. pii: S0165-6147(15)00025-5. doi: 10.1016/j.tips.2015.02.006. [Epub ahead of print] Review.

PMID:
25771972
8.

Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors.

Hołuj M, Popik P, Nikiforuk A.

Behav Pharmacol. 2015 Mar 12. [Epub ahead of print]

PMID:
25769091
9.

A Naturally Occurring Null Variant of the NMDA Type Glutamate Receptor NR3B Subunit Is a Risk Factor of Schizophrenia.

Matsuno H, Ohi K, Hashimoto R, Yamamori H, Yasuda Y, Fujimoto M, Yano-Umeda S, Saneyoshi T, Takeda M, Hayashi Y.

PLoS One. 2015 Mar 13;10(3):e0116319. doi: 10.1371/journal.pone.0116319. eCollection 2015.

10.

Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models.

Samsom JN, Wong AH.

Front Psychiatry. 2015 Feb 18;6:13. doi: 10.3389/fpsyt.2015.00013. eCollection 2015. Review.

PMID:
25762938
Free PMC Article
11.

Reproducibility of phase rotation stimulated echo acquisition mode at 3T in schizophrenia: Emphasis on glutamine.

Bustillo JR, Rediske N, Jones T, Rowland LM, Abbott C, Wijtenburg SA.

Magn Reson Med. 2015 Mar 11. doi: 10.1002/mrm.25638. [Epub ahead of print]

PMID:
25762462
12.

Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia.

Stansfield KH, Ruby KN, Soares BD, McGlothan JL, Liu X, Guilarte TR.

Transl Psychiatry. 2015 Mar 10;5:e522. doi: 10.1038/tp.2014.147.

13.

Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates.

Wang M, Arnsten AF.

Neurosci Bull. 2015 Mar 9. [Epub ahead of print]

PMID:
25754145
14.

Translational psychiatry-light at the end of the tunnel.

Jones KA, Menniti FS, Sivarao DV.

Ann N Y Acad Sci. 2015 Mar 9. doi: 10.1111/nyas.12725. [Epub ahead of print]

PMID:
25752480
15.

Gestational and early postnatal hypothyroidism alters VGluT1 and VGAT bouton distribution in the neocortex and hippocampus, and behavior in rats.

Navarro D, Alvarado M, Navarrete F, Giner M, Obregon MJ, Manzanares J, Berbel P.

Front Neuroanat. 2015 Feb 17;9:9. doi: 10.3389/fnana.2015.00009. eCollection 2015.

16.

Decoupling of N-acetyl-aspartate and Glutamate within the Dorsolateral Prefrontal Cortex in Schizophrenia.

Coughlin JM, Tanaka T, Marsman A, Wang H, Bonekamp S, Kim PK, Higgs C, Varvaris M, Edden RA, Pomper M, Schretlen D, Barker PB, Sawa A.

Curr Mol Med. 2015 Mar 2. [Epub ahead of print]

PMID:
25732147
17.

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Li ML, Hu XQ, Li F, Gao WJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Feb 24;60:66-76. doi: 10.1016/j.pnpbp.2015.02.012. [Epub ahead of print] Review.

PMID:
25724760
18.

Antineuronal Antibodies Against Neurotransmitter Receptors and Synaptic Proteins in Schizophrenia: Current Knowledge and Clinical Implications.

Steiner J, Schiltz K, Bernstein HG, Bogerts B.

CNS Drugs. 2015 Feb 28. [Epub ahead of print]

PMID:
25724386
19.

Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

Javitt DC.

Ann N Y Acad Sci. 2015 Feb 26. doi: 10.1111/nyas.12689. [Epub ahead of print]

PMID:
25721890
20.

Drug development in schizophrenia: are glutamatergic targets still worth aiming at?

Goff DC.

Curr Opin Psychiatry. 2015 May;28(3):207-15. doi: 10.1097/YCO.0000000000000152.

PMID:
25710242
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk